SCHEMBL3533455

SCHEMBL3533455

O=C(O)CCCc1cc2nc(Cl)ccc2n1S(=O)(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.68
PPARA Q07869 15/20 0.68
PPARD Q03181 15/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534042 0.90 PPARG (0.70) PPARGPPARAPPARD
SCHEMBL3526991 0.88 PPARG (0.69) PPARGPPARAPPARD
SCHEMBL3532164 0.88 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL3530519 0.86 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL3532162 0.86 PPARG (0.65) PPARGPPARAPPARD
SCHEMBL3532156 0.85 PPARG (0.69) PPARGPPARAPPARD
SCHEMBL3534145 0.85 PPARG (0.58) PPARGPPARAPPARD
SCHEMBL3530403 0.84 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL3530740 0.84 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL3531055 0.84 PPARG (0.71) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101242833-B Pyrrolopyridine derivatives and use of same as PPAR receptor modulators FOURNIER LAB SA 2012-06-27 CN disclosed
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed
CN-101242833-A Pyrrolopyridine derivatives and use of same as PPAR receptor modulators FOURNIER LAB SA (FR) 2008-08-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 1/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP PPARG 335/4885PPARA 168/4885PPARD 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.